Dare Bioscience Inc (DARE)
$3.23
+0.05
(+1.55%)▲
Performance
- $3.18$3.24$3.23
1.55%
Downside
Day's Volatility :1.85%
Upside
0.31%
- $0.43$7.56$3.23
86.69%
Downside
52 Weeks Volatility :94.31%
Upside
57.28%
Returns
| Period | Dare Bioscience Inc | |
|---|---|---|
3 Months | 4.51% | |
6 Months | 546.79% | |
1 Year | -41.52% | |
3 Years | -83.18% |
Highlights
Market Capitalization | 27.8M |
Book Value | $0.31 |
Earnings Per Share (EPS) | 32.28 |
PE Ratio | 0.1 |
PEG Ratio | 0.0 |
Wall Street Target Price | 20.33 |
Profit Margin | -253.6% |
Operating Margin TTM | -32799.12% |
Return On Assets TTM | -71.42% |
Return On Equity TTM | -994.69% |
Revenue TTM | 2.8M |
Revenue Per Share TTM | 0.36 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 9.9M |
EBITDA | -26.7M |
Diluted Eps TTM | 32.28 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.67 |
EPS Estimate Next Year | -1.36 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | -0.69 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 529.41%
Technicals Summary
Sell
Neutral
Buy
Dare Bioscience Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Dare Bioscience Inc | -6.66% | 546.79% | -41.52% | -83.18% | -63.92% |
 Regeneron Pharmaceuticals, Inc. | -11.53% | 7.92% | 21.76% | 83.48% | 256.87% |
 Novo Nordisk A/s | -12.73% | -9.68% | 25.05% | 134.03% | 343.37% |
 Alnylam Pharmaceuticals, Inc. | 6.47% | 71.74% | 59.21% | 32.07% | 248.13% |
 Vertex Pharmaceuticals Incorporated | -3.35% | 12.64% | 28.18% | 152.92% | 164.64% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Dare Bioscience Inc | 0.1 | 0.1 | 0.0 | -0.67 | -9.95 | -0.71 | NA | 0.31 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Dare Bioscience Inc | Buy | $27.8M | -63.92% | 0.1 | -253.6% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 256.87% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 343.37% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.4B | 248.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 164.64% | 32.84 | -4.74% |
Institutional Holdings
Vanguard Group Inc
3.36%Geode Capital Management, LLC
0.96%Renaissance Technologies Corp
0.74%BlackRock Inc
0.39%State Street Corp
0.24%Northern Trust Corp
0.18%
Company Information
daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.
Organization | Dare Bioscience Inc |
Employees | 23 |
CEO | Ms. Sabrina Martucci Johnson |
Industry | Health Technology |
Discover More
Generations Bancorp Ny Inc
$3.23
+1.55%
Innovator Us Equity Accelerated Etf - April
$3.23
+1.55%
First Trust Exchange-traded
$3.23
+1.55%
Udemy, Inc.
$3.23
+1.55%
Trubridge Inc
$3.23
+1.55%
Stone Ridge 2049 Inflation-protected Longevity Income Etf
$3.23
+1.55%
Farmers National Banc Corp
$3.23
+1.55%
Bbb Foods Inc.
$3.23
+1.55%
Spdr Ssga Us Eq Prem Inc Etf
$3.23
+1.55%